Publications

2018

Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies.
Haldrup C, Pedersen AL, Øgaard N, Strand SH, Høyer S, Borre M, Ørntoft TF, Sørensen KD.
Mol Oncol. 2018 Feb 21. doi: 10.1002/1878-0261.12183. [Epub ahead of print] PubMed

Perceptions about screening for prostate cancer using genetic lifetime risk assessment: a qualitative study.
Kirkegaard P, Edwards A, Nielsen TLO, Ørntoft TF, Sørensen KD, Borre M, Bro F.
BMC Fam Pract . 2018 Feb 17;19(1):32. doi: 10.1186/s12875-018-0717-6. PubMed

Molecular-Subtype-Specific Biomarkers Improve Prediction of Prognosis in Colorectal Cancer.
Bramsen JB, Rasmussen MH, Ongen H, Mattesen TB, Ørntoft MW, Árnadóttir SS, Sandoval J, Laguna T, Vang S, Øster B, Lamy P, Madsen MR, Laurberg S, Esteller M, Dermitzakis ET, Ørntoft TF, Andersen CL.
Cell Rep. 2017 May 9;19(6):1268-1280. doi: 10.1016/j.celrep.2017.04.045. PubMed

Molecular markers increase precision of the European Association of Urology non-muscle invasive bladder cancer progression risk groups.
Van Kessel KE, van der Keur KA, Dyrskjøt L, Algaba F, Welvaart NY, Beukers W, Segersten U, Keck B, Maurer T, Simic T, Horstmann M, Grimm MO, Hermann GG, Mogensen K, Hartmann A, Harving N, Petersen AC, Jensen JB, Junker K, Boormans JL, Real FX, Malats N, Malmström PU, Ørntoft TF, Zwarthoff EC.
Clin Cancer Res. 2018 Jan 24. pii: clincanres.2719.2017. doi: 10.1158/1078-0432.CCR-17-2719. [Epub ahead of print] PubMed

Pan-cancer screen for mutations in non-coding elements with conservation and cancer specificity reveals correlations with expression and survival.
Hornshøj H, Nielsen MM, Sinnott-Armstrong NA, Świtnicki MP, Juul M, Madsen T, Sallari R, Kellis M, Ørntoft T, Hobolth A, Pedersen JS.
NPJ Genom Med. 2018 Jan 11;3:1. doi: 10.1038/s41525-017-0040-5. eCollection 2018. PubMed